Avapritinib and corticosteroids in advanced systemic mastocytosis with tumoral CMML and associated thrombocytopenia. [PDF]
Abakarim O +7 more
europepmc +1 more source
KIT D816V–mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progression [PDF]
Andrés C. García‐Montero +12 more
openalex +1 more source
Avapritinib in the treatment of systemic mastocytosis with associated acute myeloid leukemia after poor graft function following allogeneic hematopoietic stem cell transplantation: a case study and review of the literature. [PDF]
Mi R +6 more
europepmc +1 more source
Overall Survival and Duration of Treatment in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib Versus Midostaurin or Best Available Therapy in a Real-World Setting [PDF]
Andreas Reiter +18 more
openalex +1 more source
Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis [PDF]
Abdulraheem Yacoub, Lindsey Prochaska
openalex +1 more source
From mechanism to management: CEREMAST perspectives on the intersection of HαT and clonal mast cell disorders. [PDF]
Polivka L, Hermine O, Rossignol J.
europepmc +1 more source
Telomere occupancy by TRF2 is altered by KIT mutations and correlates with mastocytosis regression. [PDF]
Bruneau J +23 more
europepmc +1 more source
Novel approaches in the treatment of systemic mastocytosis [PDF]
Alfonso Quintás‐Cardama +5 more
openalex +1 more source

